Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP grew its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 174.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 196,251 shares of the company's stock after acquiring an additional 124,701 shares during the period. GSA Capital Partners LLP owned about 0.19% of Arcus Biosciences worth $1,541,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of RCUS. Raymond James Financial Inc. acquired a new position in Arcus Biosciences in the fourth quarter worth about $531,000. Teacher Retirement System of Texas grew its stake in Arcus Biosciences by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock worth $223,000 after purchasing an additional 2,410 shares in the last quarter. American Century Companies Inc. grew its stake in Arcus Biosciences by 11.1% in the fourth quarter. American Century Companies Inc. now owns 97,764 shares of the company's stock worth $1,456,000 after purchasing an additional 9,782 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Arcus Biosciences in the fourth quarter worth about $207,000. Finally, Norges Bank acquired a new position in Arcus Biosciences in the fourth quarter worth about $507,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Stock Performance

Shares of RCUS traded up $0.03 during mid-day trading on Friday, reaching $9.16. 805,025 shares of the company's stock traded hands, compared to its average volume of 1,044,863. The business's 50-day moving average price is $9.13 and its 200-day moving average price is $9.66. The stock has a market capitalization of $969.91 million, a P/E ratio of -2.19 and a beta of 0.80. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.37 and a current ratio of 5.37. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $18.98.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 258.94% and a negative return on equity of 70.58%. The company had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. During the same quarter in the prior year, the business earned ($0.05) EPS. Arcus Biosciences's revenue was down 80.7% compared to the same quarter last year. Equities analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on RCUS shares. The Goldman Sachs Group cut their target price on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Barclays cut their target price on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Wedbush reissued an "outperform" rating and issued a $33.00 target price on shares of Arcus Biosciences in a report on Wednesday, May 7th. Wells Fargo & Company cut their target price on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Finally, Morgan Stanley cut their target price on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $21.29.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.